NCT02602600View on ClinicalTrials.gov

Glucagon-like Peptide-1 and Coronary Microvascular Dysfunction in Women With Angina Pectoris and no Coronary Stenosis

PHASE4CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

November 19, 2015

Primary Completion Date

April 18, 2017

Study Completion Date

April 18, 2017

Conditions
Microvascular Angina
Interventions
DRUG

Liraglutide

"* Liraglutide up to 3 mg daily injected subcutaneously (minimum 1.2 mg daily) for 12 weeks.~* Weight maintenance diet for 2 weeks"

Trial Locations (1)

2400

Bispebjerg University Hospital, Copenhagen

All Listed Sponsors
lead

Eva Prescott

OTHER

NCT02602600 - Glucagon-like Peptide-1 and Coronary Microvascular Dysfunction in Women With Angina Pectoris and no Coronary Stenosis | Biotech Hunter | Biotech Hunter